• CDC publishes first estimates of bivalent boosters' effectiveness against XBB.1.5

    1 day ago - By Healio

    The CDC for the first time has estimated how effective the bivalent COVID-19 vaccines have been against the newest dominant omicron subvariant of SARS-CoV-2.
    The subvariant, XBB.1.5, which has been described as the most transmissible SARS-CoV-2 subvariant yet, was responsible for around 49% of new COVID-19 cases in the United States last week, according to CDC tracking.
    In new estimates published Wednesday in MMWR, CDC researchers reported that vaccination with a bivalent messenger RNA booster had a relative vaccine effectiveness of 49%, 40% and 43% against symptomatic infection related to XBB
    Read more ...

     

  • Female patients disproportionately represented among COVID-19 vaccine allergy referrals

    Female patients disproportionately represented among COVID-19 vaccine allergy referrals

    1 day ago - By Healio

    Female patients were disproportionately referred to allergy clinics due to concerns about possible reactions to COVID-19 vaccination compared with male patients in Hong Kong, according to a letter published in Asthma.
    These ratios were significant for all ages and whether the referrals were before or after the vaccine was administered, Valerie Chiang, MBBS, of the division of clinical immunology, department of pathology, Queen Mary Hospital, Hong Kong, and colleagues wrote.
    The researchers examined the male-to-female ratio of 3,201 consecutive patients who were referred to the Vaccine Allergy
    Read more ...